Solute carrier family 22 member 6 - Homo sapiens (Human)

Contribute

Send feedback

Read comments (0) or add your own

Reviewed, UniProtKB/Swiss-Prot Q4U2R8 (S22A6_HUMAN)

Last modified June 16, 2009. Version 48. History...

Clusters with 100%, 90%, 50% identity |

Documents (5) |

Third-party data |

Customize display

text xml rdf/xml gff fasta

Names and origin · Protein attributes · General annotation (Comments) · Ontologies · Alternative products · Sequence annotation (Features) · Sequences · References · Web resources · Cross-references · Entry information · Relevant documents

Hide | Top

Names and origin

Protein names

Recommended name:
    Solute carrier family 22 member 6
Alternative name(s):
    Organic anion transporter 1
      Short name=hOAT1
    Renal organic anion transporter 1
      Short name=hROAT1
    PAH transporter
      Short name=hPAHT

Gene names

Name:	SLC22A6
Synonyms:	OAT1, PAHT

Organism

Homo sapiens (Human)

Taxonomic identifier

9606 [NCBI]

Taxonomic lineage

Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo

Hide | Top

Protein attributes

Sequence length	563 AA.
Sequence status	Complete.
Sequence processing	The displayed sequence is not processed.
Protein existence	Evidence at protein level.

Hide | Top

General annotation (Comments)

Function	Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) By similarity. Mediates the sodium-independent uptake of p-aminohippurate (PAH), ochratoxin (OTA), acyclovir (ACV), 3'-azido-3-'deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl) guanine (PMEG), 9-(2-phosphonylmethoxyethyl) diaminopurine (PMEDAP) and edaravone sulfate. PAH uptake is inhibited by p-chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate (DEPC), sulindac, diclofenac, carprofen, glutarate and okadaic acid By similarity. PAH uptake is inhibited by benzothiazolylcysteine (BTC), S-chlorotrifluoroethylcysteine (CTFC), cysteine S-conjugates S-dichlorovinylcysteine (DCVC), furosemide, steviol, phorbol 12-myristate 13-acetate (PMA), calcium ionophore A23187, benzylpenicillin, furosemide, indomethacin, bumetamide, losartan, probenecid, phenol red, urate, and alpha-ketoglutarate.
Subcellular location	Cell membrane; Multi-pass membrane protein Potential.
Tissue specificity	Strongly expressed in kidney and to a lower extent in liver, skeletal muscle, brain and placenta. Found at the basolateral membrane of the proximal tubule. Ref.2 Ref.3 Ref.4 Ref.5 Ref.6
Domain	Multiple cysteine residues are necessary for proper targeting to the plasma membrane By similarity.
Post-translational modification	Glycosylated. Glycosylation at Asn-113 may occur at a secondary level. Glycosylation is necesssary for proper targeting of the transporter to the plasma membrane. Ref.5 Ref.12
Sequence similarities	Belongs to the major facilitator superfamily. Organic cation transporter family.
biophysicochemical properties	Kinetic parameters: K_M=9.3 µM for PAH (isoform 1) K_M=4 µM for PAH (isoform 2) K_M=11 µM for edaravone K_M=46 µM for cidofovir K_M=30 µM for adefovir K_M=5.77 µM for 2,4-D K_M=23.5 µM for HA K_M=14 µM for IA K_M=20.5 µM for IS K_M=141 µM for CMPF V_max=534 pmol/min/mg enzyme for 2,4-D uptake V_max=430 pmol/min/mg enzyme for HA uptake V_max=110 pmol/min/mg enzyme for IA uptake V_max=216 pmol/min/mg enzyme for IS uptake V_max=801 pmol/min/mg enzyme for CMPF uptake

Hide | Top

Ontologies

Keywords
Cellular component	Cell membrane Membrane
Coding sequence diversity	Alternative splicing Polymorphism
Domain	Transmembrane
PTM	Glycoprotein
Gene Ontology (GO)
Biological process	alpha-ketoglutarate transport Ref.3 Traceable author statement. Source: ProtInc organic anion transport Ref.3 Traceable author statement. Source: ProtInc
Cellular component	basolateral plasma membrane Inferred from direct assay. Source: UniProtKB integral to plasma membrane Ref.3 Traceable author statement. Source: ProtInc membrane fraction Ref.3 Traceable author statement. Source: ProtInc
Molecular function	inorganic anion exchanger activity Inferred from direct assay. Source: UniProtKB organic anion transmembrane transporter activity Ref.3 Traceable author statement. Source: ProtInc
Complete GO annotation...

Hide | Top

Alternative products

This entry describes 4 isoforms produced by alternative splicing. [Align] [Select]

Isoform 1 (identifier: Q4U2R8-1) Also known as: OAT1-1; This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.

Isoform 2 (identifier: Q4U2R8-2) Also known as: OAT1-2; The sequence of this isoform differs from the canonical sequence as follows: 523-535: Missing.

Isoform 3 (identifier: Q4U2R8-3) Also known as: OAT1-3; The sequence of this isoform differs from the canonical sequence as follows: 455-498: Missing. 523-535: Missing.
Note: No experimental confirmation available.

Isoform 4 (identifier: Q4U2R8-4) Also known as: OAT1-4; The sequence of this isoform differs from the canonical sequence as follows: 455-498: Missing.
Note: No experimental confirmation available.

Hide | Top

Sequence annotation (Features)

Feature key

Position(s)

Length

Description

Graphical view

Feature identifier

Molecule processing

Chain

1 – 563

563

Solute carrier family 22 member 6

PRO_0000324166

Regions

Topological domain

1 – 9

Cytoplasmic Potential

Transmembrane

10 – 30

Potential

Topological domain

31 – 135

105

Extracellular Potential

Transmembrane

136 – 156

Potential

Topological domain

157 – 164

Cytoplasmic Potential

Transmembrane

165 – 187

Potential

Topological domain

188 – 190

Extracellular Potential

Transmembrane

191 – 213

Potential

Topological domain

214 – 224

Cytoplasmic Potential

Transmembrane

225 – 245

Potential

Topological domain

246 – 248

Extracellular Potential

Transmembrane

249 – 269

Potential

Topological domain

270 – 337

Cytoplasmic Potential

Transmembrane

338 – 358

Potential

Topological domain

359 – 368

Extracellular Potential

Transmembrane

369 – 389

Potential

Topological domain

390 – 395

Cytoplasmic Potential

Transmembrane

396 – 416

Potential

Topological domain

417 – 425

Extracellular Potential

Transmembrane

426 – 446

Potential

Topological domain

447 – 455

Cytoplasmic Potential

Transmembrane

456 – 475

Potential

Topological domain

476 – 484

Extracellular Potential

Transmembrane

485 – 505

Potential

Topological domain

506 – 563

Cytoplasmic Potential

Sites

Site

230

Important for interaction with cidofovir

Site

438

Important for interaction with cidofovir and PAH

Amino acid modifications

Glycosylation

N-linked (GlcNAc...) Ref.12

Glycosylation

N-linked (GlcNAc...) Ref.12

Glycosylation

N-linked (GlcNAc...) Ref.12

Glycosylation

N-linked (GlcNAc...) Ref.12

Glycosylation

113

N-linked (GlcNAc...)

Natural variations

Alternative sequence

455 – 498

Missing in isoform 3 and isoform 4.

VSP_032168

Alternative sequence

523 – 535

Missing in isoform 2 and isoform 3.

VSP_032169

Natural variant

L → P Ref.19

VAR_039682

Natural variant

R → H Lower Vmax; increase in substrate affinity and increase in the affinity for the nucleoside phosphonate analogs cidofovir, adefovir and tenofovir. dbSNP rs11568626. Ref.19 Ref.18

VAR_039683

Natural variant

104

P → L Ref.7

VAR_047878

Natural variant

293

R → W Increase in substrate affinity. dbSNP rs45607933.

VAR_039684

Experimental info

Mutagenesis

L → A: Complete loss of PAH transport activity. Ref.13

Mutagenesis

T → A: Complete loss of PAH transport activity. Ref.13

Mutagenesis

N → Q: Complete loss of PAH transport activity. Ref.12

Mutagenesis

230

Y → A: Loss of membrane protein expression and little uptake of cidofovir. Ref.16

Mutagenesis

431

K → A: Decrease in the level of membrane protein expression and 70 % loss of PAH uptake. Ref.16

Mutagenesis

438

F → A: Decrease in the level of membrane protein expression, 70 % loss of PAH uptake, increased affinity for cidofovir, lower Vmax for PAH, and lower Km and Vmax for cidofovir. Ref.16

Sequence conflict

G → S in AAD10052. Ref.3

Sequence conflict

563

L → F in AAC70004. Ref.1

Hide | Top

Sequences

Sequence		Length	Mass (Da)
Isoform 1 (OAT1-1) [UniParc]. Last modified July 19, 2005. Version 1. Checksum: 74AD3EA2678032E4 Show »	FASTA	563	61,816
10 20 30 40 50 60 MAFNDLLQQV GGVGRFQQIQ VTLVVLPLLL MASHNTLQNF TAAIPTHHCR PPADANLSKN 70 80 90 100 110 120 GGLEVWLPRD RQGQPESCLR FTSPQWGLPF LNGTEANGTG ATEPCTDGWI YDNSTFPSTI 130 140 150 160 170 180 VTEWDLVCSH RALRQLAQSL YMVGVLLGAM VFGYLADRLG RRKVLILNYL QTAVSGTCAA 190 200 210 220 230 240 FAPNFPIYCA FRLLSGMALA GISLNCMTLN VEWMPIHTRA CVGTLIGYVY SLGQFLLAGV 250 260 270 280 290 300 AYAVPHWRHL QLLVSAPFFA FFIYSWFFIE SARWHSSSGR LDLTLRALQR VARINGKREE 310 320 330 340 350 360 GAKLSMEVLR ASLQKELTMG KGQASAMELL RCPTLRHLFL CLSMLWFATS FAYYGLVMDL 370 380 390 400 410 420 QGFGVSIYLI QVIFGAVDLP AKLVGFLVIN SLGRRPAQMA ALLLAGICIL LNGVIPQDQS 430 440 450 460 470 480 IVRTSLAVLG KGCLAASFNC IFLYTGELYP TMIRQTGMGM GSTMARVGSI VSPLVSMTAE 490 500 510 520 530 540 LYPSMPLFIY GAVPVAASAV TVLLPETLGQ PLPDTVQDLE SRWAPTQKEA GIYPRKGKQT 550 560 RQQQEHQKYM VPLQASAQEK NGL « Hide
Isoform 2 (OAT1-2). Checksum: BC5D6DBDD0072D92 Show »	FASTA	550	60,318
10 20 30 40 50 60 MAFNDLLQQV GGVGRFQQIQ VTLVVLPLLL MASHNTLQNF TAAIPTHHCR PPADANLSKN 70 80 90 100 110 120 GGLEVWLPRD RQGQPESCLR FTSPQWGLPF LNGTEANGTG ATEPCTDGWI YDNSTFPSTI 130 140 150 160 170 180 VTEWDLVCSH RALRQLAQSL YMVGVLLGAM VFGYLADRLG RRKVLILNYL QTAVSGTCAA 190 200 210 220 230 240 FAPNFPIYCA FRLLSGMALA GISLNCMTLN VEWMPIHTRA CVGTLIGYVY SLGQFLLAGV 250 260 270 280 290 300 AYAVPHWRHL QLLVSAPFFA FFIYSWFFIE SARWHSSSGR LDLTLRALQR VARINGKREE 310 320 330 340 350 360 GAKLSMEVLR ASLQKELTMG KGQASAMELL RCPTLRHLFL CLSMLWFATS FAYYGLVMDL 370 380 390 400 410 420 QGFGVSIYLI QVIFGAVDLP AKLVGFLVIN SLGRRPAQMA ALLLAGICIL LNGVIPQDQS 430 440 450 460 470 480 IVRTSLAVLG KGCLAASFNC IFLYTGELYP TMIRQTGMGM GSTMARVGSI VSPLVSMTAE 490 500 510 520 530 540 LYPSMPLFIY GAVPVAASAV TVLLPETLGQ PLPDTVQDLE SRKGKQTRQQ QEHQKYMVPL 550 QASAQEKNGL « Hide
Isoform 3 (OAT1-3). Checksum: D8EBAE8A113E6C5E Show »	FASTA	506	55,858
10 20 30 40 50 60 MAFNDLLQQV GGVGRFQQIQ VTLVVLPLLL MASHNTLQNF TAAIPTHHCR PPADANLSKN 70 80 90 100 110 120 GGLEVWLPRD RQGQPESCLR FTSPQWGLPF LNGTEANGTG ATEPCTDGWI YDNSTFPSTI 130 140 150 160 170 180 VTEWDLVCSH RALRQLAQSL YMVGVLLGAM VFGYLADRLG RRKVLILNYL QTAVSGTCAA 190 200 210 220 230 240 FAPNFPIYCA FRLLSGMALA GISLNCMTLN VEWMPIHTRA CVGTLIGYVY SLGQFLLAGV 250 260 270 280 290 300 AYAVPHWRHL QLLVSAPFFA FFIYSWFFIE SARWHSSSGR LDLTLRALQR VARINGKREE 310 320 330 340 350 360 GAKLSMEVLR ASLQKELTMG KGQASAMELL RCPTLRHLFL CLSMLWFATS FAYYGLVMDL 370 380 390 400 410 420 QGFGVSIYLI QVIFGAVDLP AKLVGFLVIN SLGRRPAQMA ALLLAGICIL LNGVIPQDQS 430 440 450 460 470 480 IVRTSLAVLG KGCLAASFNC IFLYTGELYP TMIRAVTVLL PETLGQPLPD TVQDLESRKG 490 500 KQTRQQQEHQ KYMVPLQASA QEKNGL « Hide
Isoform 4 (OAT1-4). Checksum: E1748C6F9E2002F2 Show »	FASTA	519	57,357
10 20 30 40 50 60 MAFNDLLQQV GGVGRFQQIQ VTLVVLPLLL MASHNTLQNF TAAIPTHHCR PPADANLSKN 70 80 90 100 110 120 GGLEVWLPRD RQGQPESCLR FTSPQWGLPF LNGTEANGTG ATEPCTDGWI YDNSTFPSTI 130 140 150 160 170 180 VTEWDLVCSH RALRQLAQSL YMVGVLLGAM VFGYLADRLG RRKVLILNYL QTAVSGTCAA 190 200 210 220 230 240 FAPNFPIYCA FRLLSGMALA GISLNCMTLN VEWMPIHTRA CVGTLIGYVY SLGQFLLAGV 250 260 270 280 290 300 AYAVPHWRHL QLLVSAPFFA FFIYSWFFIE SARWHSSSGR LDLTLRALQR VARINGKREE 310 320 330 340 350 360 GAKLSMEVLR ASLQKELTMG KGQASAMELL RCPTLRHLFL CLSMLWFATS FAYYGLVMDL 370 380 390 400 410 420 QGFGVSIYLI QVIFGAVDLP AKLVGFLVIN SLGRRPAQMA ALLLAGICIL LNGVIPQDQS 430 440 450 460 470 480 IVRTSLAVLG KGCLAASFNC IFLYTGELYP TMIRAVTVLL PETLGQPLPD TVQDLESRWA 490 500 510 PTQKEAGIYP RKGKQTRQQQ EHQKYMVPLQ ASAQEKNGL « Hide

Hide | Top

References

	« Hide 'large scale' referencesShow 'large scale' references »
[1]	"Cloning of a human renal p-aminohippurate transporter, hROAT1." Reid G., Wolff N.A., Dautzenberg F.M., Burckhardt G. Kidney Blood Press. Res. 21:233-237(1998) [PubMed: 9762842] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION.
[2]	"Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney." Hosoyamada M., Sekine T., Kanai Y., Endou H. Am. J. Physiol. 276:F122-F128(1999) [PubMed: 9887087] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), TISSUE SPECIFICITY, FUNCTION. Tissue: Kidney.
[3]	"Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C." Lu R., Chan B.S., Schuster V.L. Am. J. Physiol. 276:F295-F303(1999) [PubMed: 9950961] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY. Tissue: Kidney.
[4]	"Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3)." Race J.E., Grassl S.M., Williams W.J., Holtzman E.J. Biochem. Biophys. Res. Commun. 255:508-514(1999) [PubMed: 10049739] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY. Tissue: Kidney.
[5]	"The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1." Cihlar T., Lin D.C., Pritchard J.B., Fuller M.D., Mendel D.B., Sweet D.H. Mol. Pharmacol. 56:570-580(1999) [PubMed: 10462545] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), GLYCOSYLATION, BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY. Tissue: Kidney.
[6]	"Genomic structure and in vivo expression of the human organic anion transporter 1 (hOAT1) gene." Bahn A., Prawitt D., Buttler D., Reid G., Enklaar T., Wolff N.A., Ebbinghaus C., Hillemann A., Schulten H.-J., Gunawan B., Fuezesi L., Zabel B., Burckhardt G. Biochem. Biophys. Res. Commun. 275:623-630(2000) [PubMed: 10964714] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 3 AND 4), BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY. Tissue: Kidney.
[7]	NIEHS SNPs program Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT LEU-104.
[8]	"Human chromosome 11 DNA sequence and analysis including novel gene identification." Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G. Sakaki Y. Nature 440:497-500(2006) [PubMed: 16554811] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
[9]	Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., Turner R. Venter J.C. Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
[10]	"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). Tissue: Colon.
[11]	"Interaction of cysteine conjugates with human and rabbit organic anion transporter 1." Groves C.E., Munoz L., Bahn A., Burckhardt G., Wright S.H. J. Pharmacol. Exp. Ther. 304:560-566(2003) [PubMed: 12538807] [Abstract] Cited for: FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES.
[12]	"Role of glycosylation in the organic anion transporter OAT1." Tanaka K., Xu W., Zhou F., You G. J. Biol. Chem. 279:14961-14966(2004) [PubMed: 14749323] [Abstract] Cited for: MUTAGENESIS OF ASN-39, GLYCOSYLATION AT ASN-39; ASN-56; ASN-92 AND ASN-97.
[13]	"Critical amino acid residues in transmembrane domain 1 of the human organic anion transporter hOAT1." Hong M., Zhou F., You G. J. Biol. Chem. 279:31478-31482(2004) [PubMed: 15145940] [Abstract] Cited for: MUTAGENESIS OF LEU-30 AND THR-36.
[14]	"Transport of the natural sweetener stevioside and its aglycone steviol by human organic anion transporter (hOAT1; SLC22A6) and hOAT3 (SLC22A8)." Srimaroeng C., Chatsudthipong V., Aslamkhan A.G., Pritchard J.B. J. Pharmacol. Exp. Ther. 313:621-628(2005) [PubMed: 15644426] [Abstract] Cited for: FUNCTION.
[15]	"Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney." Tahara H., Shono M., Kusuhara H., Kinoshita H., Fuse E., Takadate A., Otagiri M., Sugiyama Y. Pharm. Res. 22:647-660(2005) [PubMed: 15846473] [Abstract] Cited for: BIOPHYSICOCHEMICAL PROPERTIES.
[16]	"A three-dimensional model of human organic anion transporter 1: aromatic amino acids required for substrate transport." Perry J.L., Dembla-Rajpal N., Hall L.A., Pritchard J.B. J. Biol. Chem. 281:38071-38079(2006) [PubMed: 17038320] [Abstract] Cited for: MUTAGENESIS OF TYR-230; LYS-431 AND PHE-438, SUBSTRATE-BINDING SITES, FUNCTION.
[17]	"Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate." Mizuno N., Takahashi T., Iwase Y., Kusuhara H., Niwa T., Sugiyama Y. Drug Metab. Dispos. 35:1429-1434(2007) [PubMed: 17502342] [Abstract] Cited for: FUNCTION.
[18]	"Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6)." Bleasby K., Hall L.A., Perry J.L., Mohrenweiser H.W., Pritchard J.B. J. Pharmacol. Exp. Ther. 314:923-931(2005) [PubMed: 15914676] [Abstract] Cited for: VARIANT HIS-50, CHARACTERIZATION OF VARIANT HIS-50.
[19]	"Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]." Xu G., Bhatnagar V., Wen G., Hamilton B.A., Eraly S.A., Nigam S.K. Kidney Int. 68:1491-1499(2005) [PubMed: 16164626] [Abstract] Cited for: VARIANTS PRO-7 AND HIS-50.
+	Additional computationally mapped references.

Hide | Top

Web resources

NIEHS-SNPs

Hide | Top

Cross-references

Sequence databases
	AF057039 mRNA. Translation: AAC70004.1. AB009697 mRNA. Translation: BAA75072.1. AB009698 mRNA. Translation: BAA75073.1. AF104038 mRNA. Translation: AAD10052.1. AF097490 mRNA. Translation: AAD19356.1. AF124373 mRNA. Translation: AAD55356.1. AJ249369 Genomic DNA. Translation: CAB77184.1. AJ251529 mRNA. Translation: CAB94830.1. AJ271205 mRNA. Translation: CAB97249.1. EU567146 Genomic DNA. Translation: ACB21049.1. AP001858 Genomic DNA. No translation available. CH471076 Genomic DNA. Translation: EAW74129.1. CH471076 Genomic DNA. Translation: EAW74130.1. CH471076 Genomic DNA. Translation: EAW74131.1. CH471076 Genomic DNA. Translation: EAW74132.1. BC033682 mRNA. Translation: AAH33682.1.
IPI	IPI00006296. IPI00011035. IPI00645624. IPI00654872.
RefSeq	NP_004781.2. NP_695008.1. NP_695009.1. NP_695010.1.
UniGene	Hs.369252
3D structure databases
ModBase	Search...
Protein-protein interaction databases
IntAct	Q4U2R8. 1 interaction.
Proteomic databases
PRIDE	Q4U2R8.
Genome annotation databases
Ensembl	ENSG00000197901. Homo sapiens. [Contig view]
GeneID	9356.
KEGG	hsa:9356.
Organism-specific databases
GeneCards	GC11M062500.
HGNC	HGNC:10970. SLC22A6.
MIM	607582. gene.
PharmGKB	PA388.
GenAtlas	Search...
Phylogenomic databases
HOGENOM	Q4U2R8.
HOVERGEN	Q4U2R8.
OMA	Q4U2R8. SSFNCIF.
Gene expression databases
ArrayExpress	Q4U2R8.
Bgee	Q4U2R8.
Family and domain databases
InterPro	IPR011701. MFS_1. IPR004749. Orgcat_transp. [Graphical view]
Pfam	PF07690. MFS_1. 1 hit. [Graphical view]
TIGRFAMs	TIGR00898. 2A0119. 1 hit.
PROSITE	PS50850. MFS. 1 hit. [Graphical view]
ProtoNet	Search...
Other Resources
NextBio	35037.
SOURCE	Search...

Hide | Top

Entry information

Entry name

S22A6_HUMAN

Accession

Primary (citable) accession number: Q4U2R8
Secondary accession number(s): A8MY93

Q9UEQ8

Entry history

Integrated into UniProtKB/Swiss-Prot:	March 18, 2008
Last sequence update:	July 19, 2005
Last modified:	June 16, 2009
This is version 48 of the entry and version 1 of the sequence. [Complete history]

Entry status

Reviewed (UniProtKB/Swiss-Prot)

Annotation project

HPI (Human Proteome Initiative)

Hide | Top

Relevant documents

Human chromosome 11

Human chromosome 11: entries, gene names and cross-references to MIM

Human entries with polymorphisms or disease mutations

List of human entries with polymorphisms or disease mutations

Human polymorphisms and disease mutations

Index of human polymorphisms and disease mutations

MIM cross-references

Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot

SIMILARITY comments

Index of protein domains and families

Names and origin

Protein attributes

General annotation (Comments)

Ontologies

Alternative products

Sequence annotation (Features)

Molecule processing

Regions

Sites

Amino acid modifications

Natural variations

Experimental info

Sequences

References

Web resources

Cross-references

Sequence databases

3D structure databases

Protein-protein interaction databases

Proteomic databases

Genome annotation databases

Organism-specific databases

Phylogenomic databases

Gene expression databases

Family and domain databases

Other Resources

Entry information

Relevant documents